OpenLB
Open Library of Bioscience
Advanced Search
Nutrition & metabolism
2020;17 74.

Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial.

Saber Jafari-Maskouni, Mansour Shahraki, Milad Daneshi-Maskooni, Alireza Dashipour, Ali Shamsi-Goushki, Zinat Mortazavi
Author Information
  1. Saber Jafari-Maskouni: Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
  2. Mansour Shahraki: Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
  3. Milad Daneshi-Maskooni: Department of Nutrition, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran. ORCID
  4. Alireza Dashipour: Department of Food Science and Nutrition, Cellular and Molecular Research Center, Department of Clinical Biochemistry, Zahedan University of Medical Sciences, Zahedan, Iran.
  5. Ali Shamsi-Goushki: Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
  6. Zinat Mortazavi: Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
PMID: 32863846 DOI: 10.1186/s12986-020-00494-4

Abstract

BACKGROUND: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the metabolic and clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with T2DM.
METHODS: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Due to the eligibility criteria, 60 participants were randomly placed into two groups, namely placebo ( = 30) and BP ( = 30). The supplementation was considered one 1000 mg capsule 2 times /day BP by meals (lunch and dinner) for 8 weeks. Physical activity levels, dietary intakes, anthropometric measurements [weight, height, and waist circumference], glycemic indices [fasting blood glucose (FBG) and insulin (FBI)], blood lipids [triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)], and serum nesfatin-1 level were determined. Homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative insulin sensitivity checks index (QUICKI), and Body Mass Index (BMI) were computed.
RESULTS: In comparison with placebo, BP significantly decreased FBG, HOMA-IR, and BMI (). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant ().
CONCLUSION: BP supplementation improved serum glucose indices and BMI among overweight and obese T2DM patients. Further trials are needed to confirm results.
TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/trial/35752.

Keywords

Bunium Persicum Glucose indices Lipids Nesfatin-1 Type 2 diabetes

References

  1. Clin Endocrinol (Oxf). 2010 Oct;73(4):484-90 [PMID: 20550530]
  2. J Am Coll Nutr. 2020 May-Jun;39(4):345-351 [PMID: 31369353]
  3. Pak J Pharm Sci. 2010 Jul;23(3):300-4 [PMID: 20566444]
  4. Curr Vasc Pharmacol. 2020;18(2):104-109 [PMID: 30961501]
  5. Nat Prod Res. 2006 Jul 20;20(9):882-6 [PMID: 16753927]
  6. Regul Pept. 2010 Jan 8;159(1-3):72-7 [PMID: 19896982]
  7. Prague Med Rep. 2015;116(2):87-111 [PMID: 26093665]
  8. Reprod Fertil Dev. 2020 Feb;32(3):313-321 [PMID: 31661670]
  9. Phytother Res. 2016 Jun;30(6):981-7 [PMID: 26988309]
  10. Drug Res (Stuttg). 2018 Nov;68(11):637-647 [PMID: 29635674]
  11. Iran J Med Sci. 2017 Jul;42(4):369-376 [PMID: 28761203]
  12. PLoS One. 2010 Dec 03;5(12):e15201 [PMID: 21151928]
  13. Br J Nutr. 2013 Oct;110(8):1434-43 [PMID: 23507295]
  14. Endocrinology. 2012 Apr;153(4):1959-71 [PMID: 22334726]
  15. Evid Based Complement Alternat Med. 2013;2013:928582 [PMID: 24319489]
  16. Diabetes Metab Syndr. 2015 Oct-Dec;9(4):292-8 [PMID: 25470645]
  17. Endocr J. 2009;56(4):537-43 [PMID: 19461159]
  18. Pharm Biol. 2011 Feb;49(2):146-51 [PMID: 20942602]
  19. J Evid Based Complementary Altern Med. 2017 Oct;22(4):996-1001 [PMID: 28397551]
  20. J Oleo Sci. 2014;63(7):741-6 [PMID: 24919477]
  21. Regul Pept. 2012 Jan 10;173(1-3):82-5 [PMID: 22036920]
  22. J Agric Food Chem. 2005 Apr 6;53(7):2446-50 [PMID: 15796577]
  23. Nutr Metab (Lond). 2019 Jan 28;16:8 [PMID: 30705687]
  24. Diabetes Metab Syndr. 2016 Apr-Jun;10(2 Suppl 1):S114-8 [PMID: 27312373]
  25. Phytother Res. 2007 May;21(5):427-33 [PMID: 17236166]
  26. Endocrinology. 2009 Jan;150(1):232-8 [PMID: 18818289]
  27. Pak J Pharm Sci. 2012 Apr;25(2):333-7 [PMID: 22459457]
  28. PLoS One. 2013 Dec 31;8(12):e83397 [PMID: 24391760]
  29. Saudi Med J. 2011 Jul;32(7):695-700 [PMID: 21748206]
  30. Diabetes Educ. 2007 Nov-Dec;33(6):1014-29; discussion 1030-1 [PMID: 18057270]
  31. PLoS One. 2013 Aug 15;8(8):e71513 [PMID: 23967220]
  32. Nature. 2006 Oct 12;443(7112):709-12 [PMID: 17036007]
  33. Endocr J. 2011;58(4):305-13 [PMID: 21325742]
  34. BMC Complement Altern Med. 2019 Mar 12;19(1):59 [PMID: 30871514]
  35. Hum Exp Toxicol. 2019 Jul;38(7):823-832 [PMID: 30974975]
  36. Scand J Clin Lab Invest. 2012 Oct;72(6):479-83 [PMID: 22950627]
  37. Med Sci Monit. 2015 Aug 22;21:2476-84 [PMID: 26297334]
  38. Aging (Albany NY). 2020 Jan 30;12(2):1760-1777 [PMID: 32003758]
  39. J Ethnopharmacol. 2002 Oct;82(2-3):97-103 [PMID: 12241983]
  40. Complement Ther Clin Pract. 2014 Nov;20(4):297-301 [PMID: 25456022]
  41. Avicenna J Phytomed. 2014 Mar;4(2):118-26 [PMID: 25050309]
  42. J Adv Nurs. 2007 May;58(4):307-19 [PMID: 17442034]
  43. Dev Reprod. 2014 Dec;18(4):301-9 [PMID: 25949201]
  44. Pediatr Diabetes. 2013 May;14(3):189-95 [PMID: 23346951]
  45. J Diet Suppl. 2014 Mar;11(1):30-9 [PMID: 24409979]
  46. Endocrinology. 2010 Jul;151(7):3169-80 [PMID: 20427481]
  47. Food Chem. 2020 May 15;312:125829 [PMID: 31901703]
  48. Hippokratia. 2015 Jan-Mar;19(1):4-10 [PMID: 26435639]
  49. Biofactors. 2020 May;46(3):454-464 [PMID: 31898375]
  50. Neurology. 2020 Apr 21;94(16):e1749-e1756 [PMID: 31996451]
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0supplementationBPclinicalBuniumPersicumoverweightobesepatients2indicescholesterolBMImetabolicresponsesT2DMplacebo = 30bloodglucoseFBGinsulinFBI]TGTClipoproteinserumHOMA-IRQUICKINesfatin-1BACKGROUND:DiabetesmellituscommondisorderworldwideaimeddetermineBlackCarawayMETHODS:ParticipantrecruitmenttookplacediabeticclinicBu-AlihospitalZahedanDueeligibilitycriteria60participantsrandomlyplacedtwogroupsnamelyconsideredone1000 mgcapsuletimes/daymealslunchdinner8 weeksPhysicalactivitylevelsdietaryintakesanthropometricmeasurements[weightheightwaistcircumference]glycemic[fastinglipids[triglyceridetotalhigh-densityHDL-clow-densityLDL-cnesfatin-1leveldeterminedHomeostasismodelassessment-insulinresistanceQuantitativesensitivitychecksindexBodyMassIndexcomputedRESULTS:comparisonsignificantlydecreaseddifferencesLDLHDLWCsignificantCONCLUSION:improvedamongtrialsneededconfirmresultsTRIALREGISTRATION:IranianRegistryClinicalTrialsIRCTIRCT20181207041876N1Registered18/01/2019https://irctir/trial/35752Metabolicblackcarawaytypediabetes:double-blindrandomizedplacebo-controlledtrialGlucoseLipidsTypediabetes

Similar Articles

Cited By